HCA Healthcare Gets Boost from Royal Bank Of Canada's Outperform Rating

Royal Bank Of Canada reiterates its 'outperform' rating for HCA Healthcare (NYSE:HCA) in a report issued on Tuesday. The analysts maintain a price target of $435.00, indicating a potential upside of 7.24% from the company's current price.

The report is one of several recent updates from various equities analysts. In July, Cantor Fitzgerald cut their price target for HCA Healthcare to $525.00 and set an 'overweight' rating. Weiss Ratings reaffirmed a 'hold (c+)' rating on the stock, while Morgan Stanley cut their price objective to $380.00 with an 'underweight' rating.

Despite these varying opinions, HCA Healthcare currently has a consensus rating of 'Moderate Buy' among analysts, with fourteen equities research firms giving it a 'Buy' rating and eight holding a 'Hold' rating.